Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline; Gilead antiviral drug shows promise as a treatment for Ebola Sudan

Taking stock of the drug industry, from the lab to the medicine chest

March 15, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alissa Ambrose/STAT STAT+ | Bayer exec: U.S. is key in reviving beleaguered pharma's drug pipeline The company's C-suite has been on a soul-searching mission, spurred by new leadership and the realization that the company needs some fixing. By Allison DeAngelis Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan If the drug, obeldesivir, is shown to be effective in people and is approved, it would be the first oral treatment for any type of Ebola. By Helen Branswell STAT+ | Madrigal wins first U.S. approval for drug to treat liver disease MASH Rezdiffra, a pill developed by Madrigal Pharmaceuticals, targets a protein directly in the liver that reduces liver fat, inflammation, and scarring. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser